NCT01830010View on ClinicalTrials.gov

A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 28, 2013

Primary Completion Date

August 21, 2018

Study Completion Date

August 21, 2018

Conditions
Hematological Malignancies
Interventions
DRUG

Study Part 1: KRP203

All subjects will receive KRP203 for 111 days

DRUG

Study Part 2: KRP203 lower dose

DRUG

Study Part 2: KRP203 higher dose

Trial Locations (8)

4031

Novartis Investigative Site, Basel

8091

Novartis Investigative Site, Zurich

20246

Novartis Investigative Site, Hamburg

50937

Novartis Investigative Site, Cologne

75010

Novartis Investigative Site, Paris

79106

Novartis Investigative Site, Freiburg im Breisgau

93053

Novartis Investigative Site, Regensburg

07740

Novartis Investigative Site, Jena

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY